Teva's Weltruza Seen as Launch-Execution Story After Clean Label, Oppenheimer Says

MT newswire2026/10/09 16:52

12:52 PM EDT, 10/09/2026 (MT Newswires) -- Teva Pharmaceutical Industries' (TEVA) Weltruza approval removes the label risk that defined the long-acting olanzapine debate, leaving launch execution as the key question, Oppenheimer said in a note Friday. With no REMS, no post-injection observation requirement and no boxed warning for post-injection delirium sedation syndrome, Weltruza is the first practical olanzapine LAI, the firm said. Oppenheimer expects a quiet first half of 2027 focused on sampling, hospital formularies and state-by-state Medicaid additions, with meaningful revenue in the second half. It said the launch should be judged on samples, formulary wins and prescriptions, not early sales. The $3,950 monthly list price, 47% above Oppenheimer's initial assumption, signals Teva's confidence in the profile, the firm said. It assumes a 40% gross-to-net discount and flagged rebate depth as the key variable through 2027. Oppenheimer raised its price target to $52 from $50 and reiterated its outperform rating. Price: 41.64, Change: +2.39, Percent Change: +6.08

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Strategy conditionally declares daily dividends as STRC hovers below $100

Cointelegraph•2026/10/16 14:18

Devonian Health Group Says US IPO Timing Remains Undetermined

Bitget•2026/10/16 14:02

Japan’s Megabanks Finish Yen Stablecoin Pilot and Eye Real Transactions

BeInCrypto•2026/10/16 13:52

Updated 2 - CoreWeave stocks and bonds are expected to fall sharply this week as concerns over rate hikes dampen market confidence in AI investments.

路透社•2026/10/16 13:47